Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Ching

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|August 1, 1987
Resistance of cultured Lewis lung carcinoma cell lines to tiazofurinG J Finlay, L M Ching, W R Wilson, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenacS Zhou, J W Paxton, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomideS Zhou, P Kestell, M D Tingle, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptorJ H Pang, Z Cao, W R Joseph, et al.
Cancer Research|March 31, 2001
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor fociJ R Kanwar, R K Kanwar, S Pandey, et al.
British Journal of Cancer|January 1, 1997
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)M Philpott, W R Joseph, K E Crosier, et al.
Cancer Genetics and Cytogenetics|November 1, 1992
Translocation (12;17)(p11-12;q11-12): a recurrent primary rearrangement in acute leukemiaH W Liu, S K Wan, L M Ching, et al.
Cancer Research|January 1, 1991
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in miceL L Thomsen, L M Ching, L Zhuang, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)L Zhao, P Kestell, M Philpott, et al.
Biochemical Pharmacology|June 9, 1992
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analoguesL L Thomsen, L M Ching, W R Joseph, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|August 1, 1987
Resistance of cultured Lewis lung carcinoma cell lines to tiazofurinG J Finlay, L M Ching, W R Wilson, et al.
Cancer Chemotherapy and Pharmacology|May 11, 2001
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenacS Zhou, J W Paxton, P Kestell, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomideS Zhou, P Kestell, M D Tingle, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptorJ H Pang, Z Cao, W R Joseph, et al.
Cancer Research|March 31, 2001
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor fociJ R Kanwar, R K Kanwar, S Pandey, et al.
British Journal of Cancer|January 1, 1997
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)M Philpott, W R Joseph, K E Crosier, et al.
Cancer Genetics and Cytogenetics|November 1, 1992
Translocation (12;17)(p11-12;q11-12): a recurrent primary rearrangement in acute leukemiaH W Liu, S K Wan, L M Ching, et al.
Cancer Research|January 1, 1991
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in miceL L Thomsen, L M Ching, L Zhuang, et al.
Cancer Chemotherapy and Pharmacology|July 19, 2001
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA)L Zhao, P Kestell, M Philpott, et al.
Biochemical Pharmacology|June 9, 1992
Nitric oxide production in endotoxin-resistant C3H/HeJ mice stimulated with flavone-8-acetic acid and xanthenone-4-acetic acid analoguesL L Thomsen, L M Ching, W R Joseph, et al.
Pageof 8